Ellipses Pharma
Nicky Pattrick, PhD, is an experienced executive in business development, currently serving as Chief Business Development Officer and Head of Business Development & Licensing at Ellipses Pharma since January 2020. Pattrick leads the business development strategy, focusing on in- and out-licensing of clinical-stage oncology assets and portfolio management. Previously, Pattrick held the position of Director, Licensing and Growth Initiatives at GE Healthcare, overseeing global in-licensing and out-licensing transactions, and served as Senior Manager for Product Development and In-Licensing at Amdipharm Mercury Company Limited. Pattrick's earlier roles include Senior Business Development Consultant at IP Pragmatics Ltd, Manager of Worldwide Business Development at GlaxoSmithKline, and a Cell Biologist position at GlaxoSmithKline. Pattrick holds a PhD in Drug Delivery from the London School of Pharmacy and a BSc in Biochemistry with Advanced Molecular Biology from University College London.
This person is not in any teams
This person is not in any offices
Ellipses Pharma
Ellipses Pharma is an international drug development company, focused exclusively on the advancement of innovative cancer treatments through the clinic. New treatments for cancer are not progressing fast enough. Ellipses is dedicated to making a difference. Headquartered in London, Ellipses is run by a world class leadership team, overseeing a rapidly growing pipeline of high quality clinical oncology opportunities. Supported by privileged partnerships with leading academic institutions, research bodies, universities, Big Pharma and extensive professional networks, Ellipses Pharma aims to be the most direct route from the research laboratory to patients for cancer treatments. Clinical trials are the route to developing more cancer treatments. All too often they have become overly complex and expensive, slowing down the progress of new discoveries and new treatments for patients. We streamline the clinical trials process that so often inhibits the progress of new potential drugs with one overarching objective - making more treatments available to patients. Ellipses provides a permanent source of capital for the development of cancer assets via a scalable business model, and is able to conduct multiple oncology clinical trials in parallel. Supported by our Scientific Affairs Group which comprises many of the world's leading oncologists, Ellipses is taking a new, ambitious approach to significantly impact the cancer drug development market.